MHC-001

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameMHC-001

Drug Alias NamePD1 knockout engineered T cell autologous therapy (Aomiao Biotechnology/MedGenCell/Sichuan University)PD1 knockout engineered T cell autologous therapy (MedGenCell)MHC-001

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapyCell and gene therapy > Gene therapy

Mechanisms of ActionProgrammed cell death protein 1 blockers

TargetsProgrammed cell death protein 1

Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesSichuan University

China Registration ClassN/A

Develop Information

Active CompaniesChengdu Medgencell Sichuan University

Inactive CompaniesN/A

Active IndicationsCarcinoma, Non-Small-Cell Lung

Inactive IndicationsN/A

Other Information

ATC CodeN/A